Assignee
ASCENDIS PHARMA BONE DISEASES AS
DK·10 granted patents·13 pending applications·34 citations·filing 2017–2025
Top patents by PatentIndex Score
23 records- 0196US11890326B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Feb 6, 2024·5 cites·11 claims
- 0296US11793861B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Oct 24, 2023·5 cites·15 claims
- 0395US11918628B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Mar 5, 2024·4 cites·9 claims
- 0495US11857603B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Granted Jan 2, 2024·5 cites·12 claims
- 0592US11759504B2PTH compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Sep 19, 2023·6 cites·12 claims
- 0691US11590207B2Dosage regimen for a controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Feb 28, 2023·9 cites·5 claims
- 0789US2025268988A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Application pending·0 cites
- 0887US12295989B2Controlled-release PTH compoundASCENDIS PHARMA BONE DISEASES AS·Filed 2024·Granted May 13, 2025·0 cites·5 claims
- 0987US12214020B2PTH prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Granted Feb 4, 2025·0 cites·9 claims
- 1081US2023321198A1Dosage Regimen for a Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 1180US2024173385A1PTH Compounds with Low Peak-To-Trough RatiosASCENDIS PHARMA BONE DISEASES AS·Filed 2023·Application pending·0 cites
- 1277US2022008516A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 1377US2025302924A1Controlled-Release PTH CompoundASCENDIS PHARMA BONE DISEASES AS·Filed 2025·Application pending·0 cites
- 1471US2020360487A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 1571US2020376089A1Pth prodrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 1667US2020360488A1Pth compounds with low peak-to-trough ratiosASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Application pending·0 cites
- 1762US2024382567A1Long-acting PTH compound treatmentsASCENDIS PHARMA BONE DISEASES AS·Filed 2022·Application pending·0 cites
- 1861US2020276276A1PTH ProdrugsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Application pending·0 cites
- 1957US2023364199A1Improvement of physical and mental well-being of patients with hypoparathyroidismASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 2052US2023042670A1Hypoparathyroidism TreatmentASCENDIS PHARMA BONE DISEASES AS·Filed 2021·Application pending·0 cites
- 2152US2021196801A1Starting Dose of PTH ConjugatesASCENDIS PHARMA BONE DISEASES AS·Filed 2019·Application pending·0 cites
- 2248US12453778B2Incremental dose finding in controlled-release PTH compoundsASCENDIS PHARMA BONE DISEASES AS·Filed 2017·Granted Oct 28, 2025·0 cites·8 claims
- 2343US12403182B2Liquid pharmaceutical formulations of PTH conjugatesASCENDIS PHARMA BONE DISEASES AS·Filed 2020·Granted Sep 2, 2025·0 cites·8 claims
Join the waitlist — get patent alerts
Get an alert when ASCENDIS PHARMA BONE DISEASES AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →